RSV, Pfizer

US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine,
RSV Vaccine Tied to Fewer Hospitalizations, ED Visits in Older, High-Risk Adults
The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) visits in older patients during the first season of the vaccine's rollout, according to a retrospective analysis.
RSV Vaccine Shows Strong Protection for Older Adults
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or needing intensive care unit support for severe complications.
Abrysvo Vaccine Highly Effective Against RSV-Related Hospitalization in Older Adults
The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
dermatologyadvisor14h
Investigational RSV Vaccine mRNA-1345: Revaccination Safe in Eligible Older Adults
Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...
News Medical on MSN2d
Real world data highlights effectiveness of RSV vaccine
A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- ...
Vaccine for winter vomiting bug to be trialled on thousands
A vaccine is to be trialled on thousands of people to find out if it could protect against norovirus - a stomach bug that ...
What you need to know about the RSV Vaccine
The CDC recommends that all individuals aged 75 and older, as well as adults aged 60 and older who are at risk for severe RSV ...
What you need to know about the new RSV vaccine
As the days grow cooler, families across Utah are reminded that respiratory viruses, particularly Respiratory Syncytial Virus ...
Pneumonia can be a deadly complication of COVID, the flu, and RSV: What to know about pneumococcal vaccination
Pneumonia may inflame the air sacs in one or both of your lungs, notes the Mayo Clinic. The sacs can fill with pus or fluid, ...